KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Working Capital Changes (2018 - 2025)

Moderna (MRNA) has disclosed Other Working Capital Changes for 8 consecutive years, with -$261.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 227.32% to -$261.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$153.0 million, a 646.43% decrease, with the full-year FY2025 number at -$153.0 million, down 646.43% from a year prior.
  • Other Working Capital Changes was -$261.0 million for Q4 2025 at Moderna, down from $40.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.7 billion in Q1 2021 to a low of -$3.7 billion in Q2 2021.
  • A 5-year average of -$51.3 million and a median of $17.0 million in 2024 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 91550.0% in 2021; the steepest drop was 45825.0% in 2021.
  • Moderna's Other Working Capital Changes stood at $303.0 million in 2021, then soared by 654.13% to $2.3 billion in 2022, then plummeted by 205.34% to -$2.4 billion in 2023, then soared by 108.52% to $205.0 million in 2024, then plummeted by 227.32% to -$261.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Other Working Capital Changes are -$261.0 million (Q4 2025), $40.0 million (Q3 2025), and $97.0 million (Q2 2025).